What is the projected market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2035?

The projected market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2035 is 51.65 USD Billion. Read More

What was the market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2024?

The market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2024 was 17.05 USD Billion. Read More

What is the expected CAGR for the Cell and Gene Therapy Biomanufacturing Market from 2025 to 2035?

The expected CAGR for the Cell and Gene Therapy Biomanufacturing Market during the forecast period 2025 - 2035 is 10.6%. Read More

Which companies are considered key players in the Cell and Gene Therapy Biomanufacturing Market?

Key players in the market include Novartis, Gilead Sciences, Bristol-Myers Squibb, Amgen, Sangamo Therapeutics, Bluebird Bio, Celyad Oncology, Spark Therapeutics, and CRISPR Therapeutics. Read More

What are the projected valuations for Cell Therapy and Gene Therapy segments by 2035?

By 2035, the projected valuation for Cell Therapy is 19.5 USD Billion, while Gene Therapy is expected to reach 22.5 USD Billion. Read More

How do the product types in the Cell and Gene Therapy Biomanufacturing Market compare in terms of projected growth?

In 2035, Reagents are projected to reach 15.5 USD Billion, Equipment 18.6 USD Billion, and Media 17.55 USD Billion. Read More

What is the expected growth for Viral Vector Technology in the Cell and Gene Therapy Biomanufacturing Market by 2035?

Viral Vector Technology is projected to grow to 19.5 USD Billion by 2035. Read More

What is the anticipated market size for Biotechnology Companies as end users by 2035?

The anticipated market size for Biotechnology Companies as end users is expected to reach 21.0 USD Billion by 2035. Read More

What segment is projected to have the highest valuation in the Cell and Gene Therapy Biomanufacturing Market by 2035?

Gene Therapy is projected to have the highest valuation in the market, reaching 22.5 USD Billion by 2035. Read More

How does the market for Academic Research Institutes compare to Pharmaceutical Companies in 2035?

In 2035, the market for Academic Research Institutes is expected to reach 11.15 USD Billion, whereas Pharmaceutical Companies are projected to reach 19.5 USD Billion. Read More

Cell Gene Therapy Biomanufacturing Market

ID: MRFR/Pharma/20294-HCR

128 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Cell and Gene Therapy Biomanufacturing Market Research Report By Therapy Type (Cell Therapy, Gene Therapy, Combined Therapy), By Product Type (Reagents, Equipment, Media), By Technology (Viral Vector Technology, Non-Viral Vector Technology, Cell Processing Technology), By End User (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Cell Gene Therapy Biomanufacturing Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapy Type (USD Billion)
  1. 4.1.1 Cell Therapy
  2. 4.1.2 Gene Therapy
  3. 4.1.3 Combined Therapy
2. 4.2 Healthcare, BY Product Type (USD Billion)
  1. 4.2.1 Reagents
  2. 4.2.2 Equipment
  3. 4.2.3 Media
3. 4.3 Healthcare, BY Technology (USD Billion)
  1. 4.3.1 Viral Vector Technology
  2. 4.3.2 Non-Viral Vector Technology
  3. 4.3.3 Cell Processing Technology
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Biotechnology Companies
  3. 4.4.3 Academic Research Institutes
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bluebird Bio (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celyad Oncology (BE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Spark Therapeutics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 CRISPR Therapeutics (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY THERAPY TYPE
4. 6.4 US MARKET ANALYSIS BY PRODUCT TYPE
5. 6.5 US MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY THERAPY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY PRODUCT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY TECHNOLOGY
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY THERAPY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY TECHNOLOGY
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY THERAPY TYPE
17. 6.17 UK MARKET ANALYSIS BY PRODUCT TYPE
18. 6.18 UK MARKET ANALYSIS BY TECHNOLOGY
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY THERAPY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY PRODUCT TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY TECHNOLOGY
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY THERAPY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY THERAPY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY PRODUCT TYPE
30. 6.30 ITALY MARKET ANALYSIS BY TECHNOLOGY
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY THERAPY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY PRODUCT TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY TECHNOLOGY
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY THERAPY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY PRODUCT TYPE
43. 6.43 CHINA MARKET ANALYSIS BY TECHNOLOGY
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY THERAPY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY PRODUCT TYPE
47. 6.47 INDIA MARKET ANALYSIS BY TECHNOLOGY
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY THERAPY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY PRODUCT TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY TECHNOLOGY
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY THERAPY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY PRODUCT TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY TECHNOLOGY
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY THERAPY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY THERAPY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY THERAPY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY PRODUCT TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY TECHNOLOGY
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY THERAPY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY THERAPY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Therapy Type (USD Billion, 2025-2035)

Cell Therapy
Gene Therapy
Combined Therapy

Healthcare By Product Type (USD Billion, 2025-2035)

Reagents
Equipment
Media

Healthcare By Technology (USD Billion, 2025-2035)

Viral Vector Technology
Non-Viral Vector Technology
Cell Processing Technology

Healthcare By End User (USD Billion, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Academic Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”